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Background: NSCLC is the most common primary solid tumour
responsible for brain metastases (50–60% of all cases). Patients
(pts) with untreated BM have a very poor prognosis with a median
survival of approximately 1 month. Death of these pts can be
attributed to neurologic complications only in around half of
cases. Therefore, treatments directed toward extracranial metas-
tases appear essential in the management of these subjects.
Standard therapy for symptomatic multiple BM is whole-brain
radiation therapy (WBRT). The role of systemic therapies for the
treatment of BM is still under investigation due to concerns about
the penetration of chemotherapeutic agents across brain barrier
(BBB). Fotemustine (FTM) shows to be able to cross BBB whilst
CDDP remains the key drug for systemic treatment on NSCLC.
Methods: Patients with advanced NSCLC, PS 0-1 ECOG and mul-
tiple BM not amenable to locoregional treatment received 2 cycles
of FTM 80 mg/m2 d1,8 and CDDP 80 mg/m2 d1 every 3 weeks fol-
lowed by WBRT 30 Gy/3 Gy daily; 2 other cycles were included
for responding pts. Radiological response using Recist Criteria
would be allowed before WBRT to assess the role of chemother-
apy both for cranial and extra-cranial disease. Barthel ADL index
was administered every 2 cycles. This trial was designed with a
two step evaluation. After 30 pts is established first evaluation
with the aim to verify if this combination is associated with more
than 25% of response rate; subsequently, if this first step is
reached, enrolment will go on till 81 pts according to the optimal
two stage design of Simon.
Results: At 2/2008 21 patients were enrolled (M/F: 15/6, squa-
mous 3, adenocarcinoma 11, large cell 1 NSCLC 6). First interim
analysis is awaited to go on with this study
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Platinum-based doublets are considered standard therapy for
pts with advanced NSCLC. The GOIM considered P/VNR as a refer-
ence treatment. P/TXT has been reported to be active but its not
well known its real impact on quality of life. In this study patients
received either six courses of TXT/P or VNR/P with activity/safety
being the primary end-points. Secondary end-point included
time-to-progression, overall survival, and tolerability. Patients
with stage IV/IIIB, age 670 and ECOG PS 0–1, were eligible for
the study. Sample size was calculated according to Fleming’s sin-
gle-stage procedure. Responses and toxicity were assessed
according to the RECIST and NCI-CTC criteria. Patients were ran-
domized to receive: TXT 75 mg/m2 over 60 min followed by P
75 mg/m2 on day 1 every 21 d, or VNR 30 mg/m2 on days 1 and 8
and P 80 mg/m2 on day 1 every 21 days. From 12/06 to 3/08 86
patients were enrolled: Arm A 42 patients, M/F: 32/10, IIIB/IV:8/
34, squamous/not-squamous: 13/29 median age 61 (range 41–
70); Arm B 44 patients, M/F: 35/9, IIIB/IV: 10/33, squamous/not-
squamous: 14/30, median age 62 (range 44/70). To date available
toxicity data of 49 patients are the following:
Type of toxicity (49 patients) TXT/P VNR/P
Neutropenia total/G3-4 (%) 34/30 67/46
G-CSF (%) 26 35
Hemoglobin total/G3-4(%) 39/0 58/16
Darbopoetin (%) 9 19
Platelets total/G3-4 (%) 9/0 39/4
Vomiting total/G3-4 (%) 34/4 12/0
Preliminary data show an equivalence among the two treat-
ment arms regarding activity but with more hematological toxic-
ity in the VNR arm.
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